Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
Chipotle is raising its U.S. prices to offset inflation and to compensate for a promise to increase portion sizes.
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin sites for new plants beyond a $3 billion project the ...